---
schema_version: "secwatch.filing_event.v1"
accession: "0000882095-25-000044"
form_type: "8-K"
ticker: "GILD"
cik: "0000882095"
company_name: "GILEAD SCIENCES, INC."
filed_at: "2025-10-30T23:59:59+00:00"
generated_at: "2026-05-17T01:30:32.054492+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Gilead Q3 2025: Non-GAAP EPS $2.47 beats $2.02; product sales ex-Veklury up 4% to $7.1B; guidance raised

## Summary
- GAAP diluted EPS $2.43 vs $1.00; non-GAAP EPS $2.47 vs $2.02; revenue $7.8B up 3% YoY.
- Biktarvy sales up 6% to $3.7B; Descovy up 20% to $701M; HIV portfolio up 4% to $5.3B.
- Veklury down 60% to $277M; Cell therapy down 11% to $432M; Trodelvy up 7% to $357M.
- Full-year product sales guidance raised to $28.4-28.7B; non-GAAP EPS raised to $8.05-8.25.
- Operating cash flow $4.1B; dividends $1.0B; share repurchases $435M in Q3.

## SEC filing metadata
- accession: 0000882095-25-000044
- form_type: 8-K
- ticker: GILD
- cik: 0000882095
- company_name: GILEAD SCIENCES, INC.
- filed_at: 2025-10-30T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882095/000088209525000044/0000882095-25-000044-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882095/000088209525000044/gild-20251030.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000882095-25-000044
- JSON: https://secwatch.observer/filing/0000882095-25-000044.json
- Plain text: https://secwatch.observer/filing/0000882095-25-000044.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.